Leap Therapeutics Raises $58.89 Million to Advance Immuno-Oncology Programs and Digital Strategy
- Leap Therapeutics raised approximately $58.89 million through a private placement to advance immuno-oncology programs like FL-501 and sirexatamab.
- The company successfully completed a Phase 2 trial for sirexatamab, with results to be presented at ESMO Congress 2025.
- Leap plans to expand its Board of Directors and enhance its digital asset treasury strategy to support growth.
Leap Therapeutics Secures Significant Funding to Advance Immuno-Oncology Programs
Leap Therapeutics, a biotechnology firm dedicated to targeted and immuno-oncology therapeutics, successfully completes a private placement led by Winklevoss Capital, raising approximately $58.89 million. This capital infusion is crucial for the company's digital asset treasury strategy and enhances its capacity to advance key therapeutic programs, particularly FL-501 and sirexatamab. The latter recently finished a Phase 2 trial in colorectal cancer patients, with results scheduled for presentation at the upcoming ESMO Congress 2025 in Berlin on October 19. This funding not only strengthens Leap's financial position but also underscores the increasing interest in innovative cancer therapies from institutional investors.
The private placement involves the issuance of 15,212,311 shares of common stock, along with pre-funded warrants for up to 80,768,504 shares and additional warrants for 71,985,605 shares, which carry an exercise price of $0.5335 per share. This strategic financing enables Leap to bolster its research and development efforts, particularly in immuno-oncology, where there is a growing demand for effective treatment options. With the successful completion of the Phase 2 trial for sirexatamab, Leap demonstrates its commitment to pioneering therapies that could potentially improve outcomes for patients battling colorectal cancer.
In tandem with the funding, Leap Therapeutics announces plans to expand its Board of Directors to 12 members, allowing Winklevoss Capital to nominate two individuals, including the chairperson. This move reflects the company's growth trajectory and its intent to integrate diverse expertise into its governance structure. Legal advisors Morgan, Lewis & Bockius LLP and Cooley LLP assist in this transaction, ensuring compliance with regulatory frameworks. Leap anticipates providing updates on its treasury activities in the near future, indicating a proactive approach to managing its resources and strategic initiatives.
In addition to the funding, Leap Therapeutics is poised to enhance its digital asset treasury strategy, reflecting a broader trend in the biotechnology sector where companies are increasingly looking to leverage digital assets for operational and developmental advantages. This innovative approach could position Leap as a forward-thinking leader in the biotechnology industry, complementing its focus on groundbreaking therapeutic solutions. The company's dedicated efforts in immuno-oncology highlight its commitment to addressing unmet medical needs, reinforcing its role in the evolving landscape of cancer treatment.